Member Info for marve

but have you not got to kick a football to live there too lol

we have seemingly been very conservative in our approach, put the work in behind the scenes to get us to this point, we have not been issuing over the top updates, or shouting about our progress like others

once we hopefully get CE mark and orders flood in and we are delivering big orders, i hope david budd then decides to shout it to the world about us

end of week has usually seen us finish strong

and we know plenty of news is around the corner

like with gdr, no certainty until product hits the market and demand for it is there

awfully long way to fall

what about my top up early next week

should i be deramping the price down

maybe im no good at this trying to get in at the right price stuff

haha

thats definitely one way to look at it

its why i have always gone on about core market cap of the testing companies from january to now, as i felt it was a fair indication to an extent of how coronavirus has impacted them, that was my way of looking at things anyway, because it gave a comparison against others in the same sector

only so many constants to use as a guide

back when i first bought in march, if someone had said GDR would be £1.50 odd per share in mid May, fully funded after a placing, only £70m ish market cap, all the big news still to come

i would have bitten their hand off

the ride up to this point might not have been perfect, it has got a bit bumpy, but when is anything ever perfect (dam you david tyree helment catch) - anyway thats a completely different topic lol

the higher the price, the bigger the swings are in terms of monetary value, i am sure there will be plenty more down the line

onwards and upwards from here, lets hope gdr will very soon join the fight against coronavirus

topped up yesterday and hoping to get a final one in early next week when funds allow, but if we have started moving up before then, well so be it

thoughts*

have to say (and it probably is the thoughs of most), quality addition to the board here, top posting BBN

and maybe many more new ventures by gdr later down the line, i am sure with their tech and knowhow they will be looking to branch out

as sad as it is, there is an argument to say some companies needed this pandemic to be able to put them in the spotlight, otherwise they might not have had that lift to get off the ground

fair few covid stocks all taken a step back in last week or so, usual trend up and down, probably people thinking lockdown was over from sunday was one of the many factors

swings and roundabouts, once next lot of operation news lands the focus can turn away from the placing

the only thing i dont know, is what level of certain control calculus have over the investments, or on the flip side, can a client turn round and say i want my money back, to be honest the client can probably make the instruction i would say

i have never done one myself, the reason i know a bit about them is i deal with clients (me in another professional capacity), and clients have EIS and VCT investments

as i understand it, you go to calculus (or via your financial advisor) and say i have £100,000 to invest, what can you do

they offer a number of different EIS and VCT products, you pay your subscription into the pot, calculus then with your money and many other client money, they invest the money into start up / growth type companies that usually need placing capital to get going

calculus take a fee for the set up, over the course of the investment calculus manage it accordingly, then also likely take a yearly fee too

for any interested also read up how EIS and VCT investments work, it will show that they are longer term investments, they can be risky which is why they offer tax relief for the subscriber

the last investment calculus made into GDR was 2016, we are now more than 3 years after it, thus meaning for example any of their EIS investments can be sold without losing the initial tax relief

again remember calculus make their money from fees, which is not really related to the performance of the fund

calculus manage client funds, thats what they get paid to do

they operate EIS and VCT investments

and you have said it right there technik, creditability

already having a relationship in place is far better than having to start a new one off

simple business that

simple, having a product already validated cant do any harm

and in my opinion is an advantage going forward

absolutely onwards and upwards so this company can start helping the fight against coronavirus

been in here since 30p when the market cap was tiny

look at the NCYT and AVCT graph chart, the high it goes the slower the climb upwards

just how AIM works, the lower the market cap the more action, whether NCYT should be worth billions is one argument, but what the market will value it at is another

we are talking AIM not FTSE and net assets

simple comparison, approximate numbers, using a factor of x4

GDR - £75m market cap x4 becomes £300m
AVCT - £250m market cap x4 becomes £1b
NCYT - £250m market cap x4 becomes £1b

i am much more confident in GDR potentially adding £225m than the other two adding £750m

good luck with your investment, im happy staying here in GDR